

**Louisiana Department of Health  
Medicaid Pharmaceutical and Therapeutics Committee  
628 North Fourth Street  
Baton Rouge, LA  
Bienville Building  
Room #118  
April 26, 2019  
9:00 AM**

- I. Call to Order.....Marty McKay
- II. Parliamentary Business .....Marty McKay
  - A. Introduction of Members/Roll Call
  - B. Approval of November 2, 2018 Meeting Minutes
  - C. Attendance/Additional Meetings
- III. P & T Committee Overview.....Kim Sullivan
  - A. P & T Background
  - B. P & T Bylaws
- IV. Ethics Review..... Kim Sullivan
- V. Reports.....Melwyn Wendt
  - A. Prior Authorization Monthly Report
  - B. PDL Reflecting November 2, 2018 P&T Committee Recommendations
  - C. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – January 15, 2019
- VI. New Business.....Hind Douiki
  - A. Explanation of TOP\$, Monographs and Cost Sheets
  - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
    - 1. Acne Agents, Topical - New
    - 2. Analgesics, Narcotics Long
    - 3. Analgesics, Narcotics Short
    - 4. Androgenic Agents
    - 5. Angiotensin Modulator Combinations
    - 6. Angiotensin Modulators
    - 7. Antibiotics, GI
    - 8. Antibiotics, Inhaled
    - 9. Antibiotics, Topical
    - 10. Antibiotics, Vaginal
    - 11. Anticoagulants
    - 12. Antiemetic/Antivertigo Agents
    - 13. Antifungals, Oral
    - 14. Antifungals, Topical
    - 15. Antimigraine Agents, Other - New

16. Antimigraine Agents, Triptans
17. Antiparasitics, Topical
18. Antivirals, Oral
19. Antivirals, Topical
20. Beta-Blockers
21. Bladder Relaxant Preparations
22. Bone Resorption Suppression and Related Agents
23. BPH Treatments
24. Calcium Channel Blockers
25. Cephalosporins and Related Antibiotics
26. Cystic Fibrosis, Oral - New
27. Fluoroquinolones, Oral
28. GI Motility, Chronic
29. Growth Hormone
30. H. Pylori Treatment
31. Hypoglycemics, Alpha-Glucosidase Inhibitors
32. Hypoglycemics, Incretin Mimetics/Enhancers
33. Hypoglycemics, Insulin and Related Agents
34. Hypoglycemics, Meglitinides
35. Hypoglycemics, Metformins
36. Hypoglycemics, SGLT2
37. Hypoglycemics, Sulfonylureas
38. Hypoglycemics, TZD
39. Immunosuppressives, Oral
40. Lincosamides/Oxazolidinones/Streptogramins
41. Lipotropics, Other
42. Lipotropics, Statins
43. Macrolides/Ketolides
44. Multiple Sclerosis Agents
45. Nitrofurans Derivatives
46. Opiate Dependence Treatments
47. PAH Agents, Oral and Inhaled
48. Pancreatic Enzymes
49. Pediatric Vitamin Preparations - New
50. Phosphate Binders
51. Pituitary Suppressive Agents, LHRH
52. Platelet Aggregation Inhibitors
53. Proton Pump Inhibitors
54. Sinus Node Inhibitors - New
55. Skeletal Muscle Relaxants
56. Tetracyclines
57. Ulcerative Colitis Agents
58. Uterine Disorder Treatments - New
59. Vasodilators, Coronary

C. Hepatitis C

- VII. New & Other Single Drug Reviews.....Hind Douiki
  - 60. Antipsychotics – Abilify Mycite<sup>®</sup>
  - 61. Colony Stimulating Factors - Udenyca<sup>®</sup>
  - 62. COPD Agents – Yupelri<sup>®</sup>
  - 63. Neuropathic Pain – Ztlido<sup>®</sup>
  - 64. Ophthalmics, Anti-Inflammatories – Inveltys<sup>®</sup>
  - 65. Ophthalmics, Anti-Inflammatory/Immunomodulator – Cequa<sup>®</sup>
  - 66. Ophthalmics, Glaucoma Agents – Xelpros<sup>®</sup>
  - 67. Steroids, Topical, Very High - Bryhali<sup>®</sup>
  - 68. Steroids, Topical, Very High – Lexette<sup>®</sup>
  
- VIII. Hepatitis C Model.....Dr. Marcus Bachhuber
  
- IX. Other Business
  
- X. Next Steps
  - A. Proposed Therapeutic Classes to be Reviewed at Next Meeting
  
- XI. Next Meeting Date – Wednesday, November 6, 2019
  
- XII. Public Testimony